Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical ...
This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...
Expanded indication for AKEEGA® (niraparib and abiraterone acetate dual-action tablet) plus prednisone marks the first FDA-approved precision medicine combination treatment for patients with BRCA2-mut ...
Zydus introduces biosimilar denosumab 120 mg SC – protecting bone health in cancer patients: Our Bureau, Mumbai Wednesday, December 10, 2025, 13:30 Hrs [IST] Zydus Lifesciences ...
Capital Market on MSN
Zydus Lifesciences gains after launching denosumab biosimilar
Denosumab is a monoclonal antibody with several indications related to bone health, primarily used in the treatment of ...
JANX007 shows significant PSA reductions and favorable rPFS in mCRPC patients, with a manageable safety profile. The trial identifies 6 mg and 9 mg as optimal doses, balancing safety and efficacy.
To our knowledge, this is the greatest survival benefit, based upon hazard ratio, ever seen in a prostate cancer,” said study presenter Stephen J. Freedland, MD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback